Phase I, Double-Blind, Randomized Study of Daily, Twice-Weekly and Once-Weekly APL 2 in Healthy Volunteers

Trial Profile

Phase I, Double-Blind, Randomized Study of Daily, Twice-Weekly and Once-Weekly APL 2 in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs APL 2 (Primary)
  • Indications Dry age-related macular degeneration; Ischaemia; Paroxysmal nocturnal haemoglobinuria; Wet age-related macular degeneration
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 28 Sep 2017 An extra subject will receive placebo in Cohort 3 to allow for Sentinel subjects (1 active and 1 placebo) to be dosed a day ahead of the remaining subjects in Cohort 3 (3 active and 1 placebo), yet still maintain the blind. The Sentinel subjects will be included in Cohort 3 as an additional safety precaution, because the planned dose of APL 2 (2,600 mg once per week) is higher than the highest single dose administered to date (1,440 mg). and Blood and urine samples will be collected on D
    • 28 Sep 2017 Planned number of patients changed from 20 to 22.
    • 28 Sep 2017 Planned End Date changed from 30 Apr 2018 to 31 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top